The following Structured Product Label (SPL) was submitted to the FDA by Medinatura Inc. for the product Wellmind Vertigo (NDC 62795-9003). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.
This specific version of the label includes detailed information regarding warnings:, active ingredients, inactive ingredients:, purpose, directions:, keep out of reach of children, indications:, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.
If pregnant or breast-feeding, ask
a health professional before use. Keep out of
reach of children. If symptoms persist or worsen,
a healthcare provider should be consulted. Do not
use if known sensitivity to WellMind Vertigo® or any
of its ingredients exists.
Each 300 mg tablet contains:
*Anacardium orientale 6X 10mg, *Cocculus indicus
4X 210mg, *Conium maculatum 3X 30mg,
*Petroleum 8X 20mg, *Selenium metallicum 6X
10mg, *Selenium metallicum 12X 10mg, *Selenium
metallicum 30X 10mg. *Natural
*Dextrose, *Lactose,
Magnesium stearate, *Maltodextrin
*contains one or more of these ingredients
Motion Sickness
Relief
Adults and children 12 years and
older: 1-2 tablets 3 times per day or as directed by a
health practitioner. Not to exceed 6 tablets per 24
hours. Children under 12, as directed by a health
professional. Allow to completely dissolve in the mouth
Keep out of reach of children.
For the temporary relief of minor
lightheadedness and motion sickness.
* Please review the disclaimer below.
